Clinical trials: Gemcitabine
Carcinoma, Non-Small-Cell Lung
Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer
This is a multi-center, open-label, Phase 1b, dose escalation trial of Sym004 administered in combination with 1 of 3 platinum-doublets in subjects with Stage IV Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT02083679
- Testing
- Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine, Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed, Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel
- Where
- 2 sites in United States, Germany
- Volunteers
- 15 people
- Sponsor
- EMD Serono
Advanced Biliary Tract Cancer
A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)
This study is a randomized, open-label, multicenter phase III clinical trial, aiming to evaluate the efficacy and safety of SHR-8068 combined with adbelimab and platinum-based chemotherapy in contrast to varicumab combined with…
- Trial name
- NCT07229625
- Testing
- SHR-8068 Injection, Adebrelimab Injection, Gemcitabine Hydrochloride for Injection
- Where
- China
- Volunteers
- 604 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Cancer
A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)
To characterize the safety profile of ARGX-110 administered as mono- or combination therapy to patients with NPC at various stages of its natural history (adjuvant vs. metastatic).
- Trial name
- NCT02759250
- Testing
- ARGX-110
- Where
- Belgium
- Volunteers
- 11 people
- Sponsor
- argenx
Advanced Cholangiocarcinoma, FGFR2 Gene Rearrangements
Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
This is an open-label, multinational, parallel 2-arm, randomized Phase 3 study evaluating the efficacy and safety of futibatinib versus gemcitabine-cisplatin chemotherapy as first-line treatment of participants with advanced…
- Trial name
- FOENIX-CCA3 (NCT04093362)
- Testing
- Futibatinib, Cisplatin, Gemcitabine
- Where
- 103 sites in United States, Argentina and 18 more
- Volunteers
- 10 people
- Sponsor
- Taiho Oncology, Inc.
Stage IV Pancreatic Cancer
Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer
Phase 1B: Open label (all patients receive PEGPH20+gemcitabine), dose escalation, safety and tolerability study to determine the safe dose of PEGPH20 to use in combination with gemcitabine in Stage IV previously untreated…
- Trial name
- NCT01453153
- Testing
- Gemcitabine, PEGPH20
- Where
- 12 sites in United States, Russia
- Volunteers
- 28 people
- Sponsor
- Halozyme Therapeutics
Soft Tissue Sarcoma Adult
Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma
This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
- Trial name
- NCT03056599
- Testing
- Multiple drug microinjection, CIVO device
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Presage Biosciences
Biliary Tract Carcinoma
Trial of Gemcitabine and Cisplatin in Patients With Inoperable Biliary Tract Carcinomas
The purpose of this study is to evaluate the efficacy of gemcitabine and cisplatin in Korean patients with biliary tract (bile tracts of the gallbladder or liver) cancer.
- Trial name
- NCT00490399
- Testing
- gemcitabine, cisplatin
- Where
- South Korea
- Volunteers
- 39 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in…
- Trial name
- NCT02486718
- Testing
- Atezolizumab, Cisplatin, Vinorelbine
- Where
- 216 sites in United States, Australia and 20 more
- Volunteers
- 1,280 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer
Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00054197
- Testing
- gemcitabine hydrochloride, paclitaxel poliglumex, vinorelbine tartrate
- Where
- 10 sites in United States
- Sponsor
- CTI BioPharma
Solid Tumor
Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors
The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC).
- Trial name
- NCT04064359
- Testing
- OBT076, a CD205-directed antibody-drug conjugate
- Where
- 27 sites in United States, Belgium and 3 more
- Volunteers
- 200 people
- Sponsor
- Oxford BioTherapeutics Ltd
Metastatic Pancreatic Adenocarcinoma
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
This is a phase 3 study to evaluate the efficacy of ibrutinib in combination with nab-paclitaxel and gemcitabine for the first line treatment of patients with metastatic pancreatic adenocarcinoma.
- Trial name
- NCT02436668
- Testing
- Ibrutinib, Gemcitabine, Nab-paclitaxel
- Where
- 86 sites in United States, Belgium and 6 more
- Volunteers
- 430 people
- Sponsor
- Pharmacyclics LLC.
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Adavosertib in combination with carboplatin, paclitaxel, gemcitabine, or PLD.
- Trial name
- NCT02272790
- Testing
- Adavosertib, Paclitaxel, Carboplatin
- Where
- 20 sites in United States, Canada and 1 more
- Volunteers
- 95 people
- Sponsor
- AstraZeneca
Advanced Cancer
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
This is an open-label, multi-center, Phase I trial of TST001. Subjects with locally advanced or metastatic solid tumors will be enrolled.
- Trial name
- NCT04495296
- Testing
- TST001, Oxaliplatin, Capecitabine
- Where
- 40 sites in China
- Volunteers
- 320 people
- Sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
Pancreatic Cancer
A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer
The study is being conducted to evaluate the efficacy, safety and tolerability of SHR-1701 in combination with gemcitabine and albumin paclitaxel in first-line treatment of subjects with advanced/metastatic pancreatic cancer, and…
- Trial name
- NCT04624217
- Testing
- SHR-1701
- Where
- 2 sites in China
- Volunteers
- 56 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer
Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting
Test the safety, immune response and efficacy of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to chemotherapy or CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma
- Trial name
- ECLIPSE (NCT02004262)
- Testing
- GVAX Pancreas Vaccine, CRS-207, Chemotherapy
- Where
- 21 sites in United States, Canada
- Volunteers
- 303 people
- Sponsor
- Aduro Biotech, Inc.
Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
The purpose of this study is to evaluate the safety and tolerability and overall survival (OS) of E-EDV-D682/GC in combination with gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone in participants with…
- Trial name
- Carolyn-USA (NCT07049055)
- Testing
- E-EDV-D682, EDV-GC, Gemcitabine
- Where
- 4 sites in United States
- Volunteers
- 144 people
- Sponsor
- Engeneic Pty Limited
Pancreatic Neoplasms
Combination With Gemcitabine in Advanced Pancreatic Cancer
Open-label, uncontrolled, Phase I/II study to evaluate safety and efficacy of BAY86-9766 plus gemcitabine in locally advanced, unresectable or metastatic pancreatic cancer.
- Trial name
- BAGPAC (NCT01251640)
- Testing
- BAY86-9766+Gemcitabine
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 90 people
- Sponsor
- Bayer
Carcinoma, Pancreatic Ductal
Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02)
The purpose of the study is to evaluate a new treatment strategy for advanced pancreatic cancer disease by combining the new investigational medicinal product Atu027 with the standard chemotherapeutic gemcitabine.
- Trial name
- Atu027-I-02 (NCT01808638)
- Testing
- Atu027 & gemcitabine in lead in safety period, Atu027 & gemcitabine in treatment arm 1, Atu027 & gemcitabine in treatment arm 2
- Where
- 9 sites in Germany
- Volunteers
- 29 people
- Sponsor
- Silence Therapeutics GmbH
Breast Neoplasms
Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents
This is a phase III randomized study which compares two different regimens of chemotherapy. The purpose of the study is to determine which of the two regimens will make the tumor smaller or disappear, and for how long.
- Trial name
- NCT00191438
- Testing
- gemcitabine, capecitabine, docetaxel
- Where
- 6 sites in France, Germany and 4 more
- Volunteers
- 300 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer Metastatic
A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer
This single arm study will assess the efficacy and safety of erlotinib + gemcitabine in chemotherapy-naive participants with unresectable, advanced and/or metastatic non-small cell lung cancer.
- Trial name
- NCT00701558
- Testing
- Erlotinib, Gemcitabine
- Where
- Romania
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.